Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer
Wallin, U. ; Glimelius, B. ; Jirström, Karin LU
; Darmanis, S.
; Nong, R. Y.
; Ponten, F.
; Johansson, C.
; Pahlman, L.
and Birgisson, H.
(2011)
In British Journal of Cancer
104(10).
p.1619-1627
- Abstract
- BACKGROUND: Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta superfamily and has been associated with activation of the p53 pathway in human cancer. The aim of this study was to assess the prognostic value of GDF15 in patients with colorectal cancer (CRC). METHODS: Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC. In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay. RESULTS: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR,... (More)
- BACKGROUND: Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta superfamily and has been associated with activation of the p53 pathway in human cancer. The aim of this study was to assess the prognostic value of GDF15 in patients with colorectal cancer (CRC). METHODS: Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC. In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay. RESULTS: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51). Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P = 0.041) and reduced overall survival (P = 0.002). CONCLUSION: Growth differentiation factor 15 serves as a negative prognostic marker in CRC. High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival. British Journal of Cancer (2011) 104, 1619-1627. doi: 10.1038/bjc.2011.112 www.bjcancer.com Published online 5 April 2011 (C) 2011 Cancer Research UK (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1987022
- author
- Wallin, U.
; Glimelius, B.
; Jirström, Karin
LU
; Darmanis, S.
; Nong, R. Y.
; Ponten, F.
; Johansson, C.
; Pahlman, L.
and Birgisson, H.
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- GDF15, colorectal cancer, prognostic markers, MIC-1
- in
- British Journal of Cancer
- volume
- 104
- issue
- 10
- pages
- 1619 - 1627
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000290471600014
- scopus:79955810854
- pmid:21468045
- ISSN
- 1532-1827
- DOI
- 10.1038/bjc.2011.112
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology (Malmö) (013031000), Pathology, (Lund) (013030000)
- id
- 479a02b3-750f-4f63-ba8d-9fe725d88c70 (old id 1987022)
- date added to LUP
- 2016-04-01 10:49:04
- date last changed
- 2024-01-07 01:59:04
@article{479a02b3-750f-4f63-ba8d-9fe725d88c70,
abstract = {{BACKGROUND: Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta superfamily and has been associated with activation of the p53 pathway in human cancer. The aim of this study was to assess the prognostic value of GDF15 in patients with colorectal cancer (CRC). METHODS: Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC. In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay. RESULTS: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51). Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P = 0.041) and reduced overall survival (P = 0.002). CONCLUSION: Growth differentiation factor 15 serves as a negative prognostic marker in CRC. High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival. British Journal of Cancer (2011) 104, 1619-1627. doi: 10.1038/bjc.2011.112 www.bjcancer.com Published online 5 April 2011 (C) 2011 Cancer Research UK}},
author = {{Wallin, U. and Glimelius, B. and Jirström, Karin and Darmanis, S. and Nong, R. Y. and Ponten, F. and Johansson, C. and Pahlman, L. and Birgisson, H.}},
issn = {{1532-1827}},
keywords = {{GDF15; colorectal cancer; prognostic markers; MIC-1}},
language = {{eng}},
number = {{10}},
pages = {{1619--1627}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer}},
url = {{http://dx.doi.org/10.1038/bjc.2011.112}},
doi = {{10.1038/bjc.2011.112}},
volume = {{104}},
year = {{2011}},
}